Page 15 - EASL POSTGRADUATE COURSE

MELD Model for End-Stage Liver Disease PUFA polyunsaturated fatty acid

MetS metabolic syndrome ROS reactive oxygen species

MHO metabolically healthy obese RXR retinoid X receptor

MRE magnetic resonance elastography RYGB Roux en-Y gastric bypass

MRI magnetic resonance imaging SAF score steatosis, activity, and fibrosis score

mTOR mechanistic target of rapamycin SAM s-adenosylmethionine

NAFL non-alcoholic fatty liver SAT subcutaneous adipose tissue

NAFLD non-alcoholic fatty liver disease SCD1 Stearoyl-CoA desaturase 1

NAS NAFLD activity score SFA saturated fatty acid

NASH non-alcoholic steatohepatitis SNP single nucleotide polymorphism

NEMO NF-kB essential modulator SREBP1c sterol regulatory element binding
protein 1c
NF-kB NF-kappaB transcription factor

NFS NAFLD fibrosis score STAT3 signal transducer and activator of
transcription 3

NPV negative predictive value T2DM type 2 diabetes mellitus

OCA obeticholic acid TAK1 transforming growth factor beta-
activated kinase 1
OGIS oral glucose insulin sensitivity index

OGTT oral glucose tolerance test TE transient elastography

OLT orthotopic liver transplant TG/TAG triglyceride/triacylglyceride

OR odds ratio TLR Toll-like receptor

OSAS obstructive sleep apnea syndrome TNFα tumor necrosis factor alpha

PC phosphocholine UNL upper normal limit

PCOS polycystic ovary syndrome VAT visceral adipose tissue

PDGFR platelet-derived growth factor VLCFA very long chain fatty acid
receptor
VLDL very-low-density lipoprotein

PI3K phosphoinositide 3-kinase

PNPLA3 patatin-like phospholipase domain
containing 3 gene

PPAR peroxisome proliferator-activated
receptor

PPV positive predictive value

PTEN phosphatase and tensin homolog

The International Liver Congress™ 2015 • Vienna, Austria • April 22–23, 2015 15